S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
pixel
Musk says Twitter deal could move ahead with 'bot' info
Senate parliamentarian OKs most of Dems' drug price controls
Dems' climate, energy, tax bill clears initial Senate hurdle
Senate rules referee weakens Dem drug plan in economic bill
Demand for grocery delivery cools as food costs rise
Venezuela, Colombia border areas hopeful as reopening looms
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
pixel
Musk says Twitter deal could move ahead with 'bot' info
Senate parliamentarian OKs most of Dems' drug price controls
Dems' climate, energy, tax bill clears initial Senate hurdle
Senate rules referee weakens Dem drug plan in economic bill
Demand for grocery delivery cools as food costs rise
Venezuela, Colombia border areas hopeful as reopening looms
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
pixel
Musk says Twitter deal could move ahead with 'bot' info
Senate parliamentarian OKs most of Dems' drug price controls
Dems' climate, energy, tax bill clears initial Senate hurdle
Senate rules referee weakens Dem drug plan in economic bill
Demand for grocery delivery cools as food costs rise
Venezuela, Colombia border areas hopeful as reopening looms
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
pixel
Musk says Twitter deal could move ahead with 'bot' info
Senate parliamentarian OKs most of Dems' drug price controls
Dems' climate, energy, tax bill clears initial Senate hurdle
Senate rules referee weakens Dem drug plan in economic bill
Demand for grocery delivery cools as food costs rise
Venezuela, Colombia border areas hopeful as reopening looms
NYSE:GKOS

Glaukos (GKOS) Stock Forecast, Price & News

$52.98
-0.52 (-0.97%)
(As of 08/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$51.63
$53.44
50-Day Range
$40.83
$53.85
52-Week Range
$33.33
$64.49
Volume
635,685 shs
Average Volume
507,366 shs
Market Capitalization
$2.51 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$57.38

Glaukos MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
8.3% Upside
$57.38 Price Target
Short Interest
Healthy
3.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.95
Upright™ Environmental Score
News Sentiment
0.00mentions of Glaukos in the last 14 days
Based on 22 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.03) to ($1.59) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.78 out of 5 stars

Medical Sector

928th out of 1,283 stocks

Surgical & Medical Instruments Industry

100th out of 130 stocks

Glaukos logo

About Glaukos (NYSE:GKOS) Stock

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.

Glaukos Trading Down 1.0 %

Shares of NYSE:GKOS traded down $0.52 on Friday, hitting $52.98. 635,685 shares of the company's stock were exchanged, compared to its average volume of 507,366. Glaukos has a 12 month low of $33.33 and a 12 month high of $64.49. The stock has a market capitalization of $2.51 billion, a price-to-earnings ratio of -44.52 and a beta of 1.41. The business's 50 day simple moving average is $47.24 and its two-hundred day simple moving average is $50.28. The company has a debt-to-equity ratio of 0.63, a current ratio of 6.78 and a quick ratio of 8.39.

Glaukos (NYSE:GKOS - Get Rating) last released its earnings results on Wednesday, May 4th. The medical instruments supplier reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.14. Glaukos had a negative return on equity of 13.82% and a negative net margin of 19.35%. The business had revenue of $67.70 million during the quarter, compared to the consensus estimate of $60.85 million. During the same period last year, the company earned ($0.21) earnings per share. The business's revenue for the quarter was down .4% compared to the same quarter last year. Analysts anticipate that Glaukos will post -2.03 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on GKOS shares. Citigroup lifted their price objective on shares of Glaukos from $49.00 to $54.00 in a research note on Thursday. Stifel Nicolaus raised shares of Glaukos from a "hold" rating to a "buy" rating and lifted their price objective for the stock from $40.00 to $60.00 in a research note on Tuesday, July 12th. Finally, BTIG Research lifted their price objective on shares of Glaukos from $61.00 to $66.00 in a research note on Monday, April 18th. One research analyst has rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $57.38.

Receive GKOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Glaukos and its competitors with MarketBeat's FREE daily newsletter.

GKOS Stock News Headlines

Glaukos: Q2 Earnings Snapshot - Greenwich Time
Glaukos Q2 2022 Earnings Preview - Seeking Alpha
See More Headlines

Receive GKOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Glaukos and its competitors with MarketBeat's FREE daily newsletter.

GKOS Company Calendar

Last Earnings
11/04/2021
Today
8/07/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Employees
727
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$57.38
High Stock Price Forecast
$68.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
+8.3%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
9 Analysts

Profitability

Net Income
$-49,590,000.00
Pretax Margin
-19.33%

Debt

Sales & Book Value

Annual Sales
$294.01 million
Book Value
$11.88 per share

Miscellaneous

Free Float
43,500,000
Market Cap
$2.51 billion
Optionable
Optionable
Beta
1.41

Key Executives

  • Mr. Thomas William Burns (Age 61)
    Chairman & CEO
    Comp: $1.96M
  • Mr. Joseph E. Gilliam (Age 45)
    Pres & COO
    Comp: $991.52k
  • Mr. Chris M. Calcaterra (Age 62)
    Exec. VP of Global Commercial Operations
    Comp: $1M
  • Dr. Mory Gharib Ph.D.
    Co-Founder
  • Mr. Alex R. Thurman (Age 52)
    Sr. VP & CFO
  • Mr. Christopher William Lewis
    VP of Investor Relations & Corp. Affairs
  • Ms. Diane W. Biagianti (Age 62)
    Sr. VP & Gen. Counsel
  • Ms. Diana A. Scherer
    VP of Compliance & Deputy Gen. Counsel
  • Ms. Michele M. Allegretto
    Sr. VP of HR
  • Mr. David S. Haffner
    Sr. VP of New Technologies













GKOS Stock - Frequently Asked Questions

Should I buy or sell Glaukos stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Glaukos stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GKOS, but not buy additional shares or sell existing shares.
View analyst ratings for Glaukos
or view top-rated stocks.

What is Glaukos' stock price forecast for 2022?

9 analysts have issued twelve-month price objectives for Glaukos' shares. Their GKOS stock forecasts range from $40.00 to $68.00. On average, they predict Glaukos' share price to reach $57.38 in the next year. This suggests a possible upside of 8.3% from the stock's current price.
View analysts' price targets for Glaukos
or view top-rated stocks among Wall Street analysts.

How has Glaukos' stock price performed in 2022?

Glaukos' stock was trading at $44.44 on January 1st, 2022. Since then, GKOS shares have increased by 19.2% and is now trading at $52.98.
View the best growth stocks for 2022 here
.

When is Glaukos' next earnings date?

Glaukos is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our earnings forecast for Glaukos
.

How were Glaukos' earnings last quarter?

Glaukos Co. (NYSE:GKOS) issued its earnings results on Thursday, November, 4th. The medical instruments supplier reported $0.13 EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.37. The medical instruments supplier earned $74.71 million during the quarter, compared to analyst estimates of $72.73 million. Glaukos had a negative net margin of 19.35% and a negative trailing twelve-month return on equity of 13.82%. The firm's revenue for the quarter was up 15.2% on a year-over-year basis. During the same period last year, the company posted ($0.09) EPS.

What guidance has Glaukos issued on next quarter's earnings?

Glaukos updated its FY 2022 earnings guidance on Wednesday, August, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $275.00 million-$280.00 million, compared to the consensus revenue estimate of $274.39 million.

What is Thomas W. Burns' approval rating as Glaukos' CEO?

10 employees have rated Glaukos CEO Thomas W. Burns on Glassdoor.com. Thomas W. Burns has an approval rating of 100% among Glaukos' employees. This puts Thomas W. Burns in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Glaukos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include NVIDIA (NVDA), Marvell Technology (MRVL), PTC Therapeutics (PTCT), PayPal (PYPL), QUALCOMM (QCOM), Alibaba Group (BABA), Teladoc Health (TDOC), Intel (INTC), Advanced Micro Devices (AMD) and Boeing (BA).

When did Glaukos IPO?

(GKOS) raised $76 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

What is Glaukos' stock symbol?

Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

Who are Glaukos' major shareholders?

Glaukos' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (1.90%), Riverbridge Partners LLC (1.36%), Interwest Venture Management Co. (0.74%), Taylor Frigon Capital Management LLC (0.20%), State of New Jersey Common Pension Fund D (0.12%) and Granite Investment Partners LLC (0.10%). Company insiders that own Glaukos stock include Joseph E Gilliam, Thomas William Burns and William J Phd Link.
View institutional ownership trends for Glaukos
.

How do I buy shares of Glaukos?

Shares of GKOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Glaukos' stock price today?

One share of GKOS stock can currently be purchased for approximately $52.98.

How much money does Glaukos make?

Glaukos (NYSE:GKOS) has a market capitalization of $2.51 billion and generates $294.01 million in revenue each year. The medical instruments supplier earns $-49,590,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis.

How many employees does Glaukos have?

Glaukos employs 727 workers across the globe.

How can I contact Glaukos?

Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The official website for Glaukos is www.glaukos.com. The medical instruments supplier can be reached via phone at (949) 367-9600, via email at investors@glaukos.com, or via fax at 949-367-9984.

This page (NYSE:GKOS) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.